期刊文献+

纤溶酶原激活物抑制剂-1在SD大鼠胰腺的表达

Expression of plasminogen activator inhibitor 1 in the pancreas of SD rat
原文传递
导出
摘要 目的研究纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)在大鼠胰腺组织中的表达,为临床上对重症急性胰腺炎(severe acute pancreatitis,SAP)患者使用抗凝剂及抗血小板药物治疗提供理论依据,并为进一步研究应用PAI-1抑制剂治疗胰腺炎提供形态学依据。方法应用免疫荧光组织化学双重标记技术,在激光共聚焦显微镜观察PAI-1在大鼠胰腺组织中的分布。结果 PAI-1免疫反应阳性细胞分布在SD大鼠胰腺的外分泌腺腺泡细胞,以及内分泌腺D细胞及PP细胞,阳性物质分布于细胞质。结论 PAI-1可能在胰腺起着非常重要的作用,为进一步研究应用PAI-1抑制剂治疗胰腺炎提供了形态学依据。 Objective To investigate the distribution of plasminogen activator inhibitor 1 (PAl-l) in the pancreas of normal SD rat to provide morphologic basis for further research on using PAI-1 inhibitor to cure acute pancreatitis. Methods The immunofluorescence histochemical double-labeling technique was used to observe the localization of PAI-1 in the pancreas of normal SD rats under a confocal laser-scanrfing microscope. Results PAI-1 immunoreactivity was found to be localized in the cytoplasm of the acinar cells, somatostatin-secreting cells(D cells), and pancreatic polypeptide (PP)-secreting cells(PP cells). Conclusion PAI-1 might play a critical role in the pancreas, which will provide morphologic basis for further research on using PAI-1 inhibitor to cure acute pancreatifis.
出处 《解剖科学进展》 CAS 2013年第6期506-508,共3页 Progress of Anatomical Sciences
基金 辽宁省科技计划项目(No.2009225022)
关键词 纤溶酶原激活物抑制剂-1 胰腺 大鼠 双重免疫荧光组织化学 plasminogen activator inhibitor 1 pancreas rat double-labeling immunofluorescence histochemistry
  • 相关文献

参考文献8

二级参考文献48

  • 1李苏娅.2443例血浆D-二聚体异常的临床意义探讨[J].中国优生与遗传杂志,2007,15(5):38-38. 被引量:12
  • 2Medved L ,Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin[J]. Thromb Haemost, 2003 (89) : 409-419.
  • 3Well P S. Integrated strategies for the diagnosis of venous thromboembolism [J]. J Thromb Haemost, 2007,5(1):41-50.
  • 4Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy [J]. N Engl J Med,2006,355(17):1 780-1 789.
  • 5Legnani C, Palareti G, Cosmi B, et al. Different cut off values of quantitative D-dimer methods to predict the risk of venous throm boembolism recurrence:a post-hoc analysis of the prolong study[J]. Haematologica, 2008,93 (6) : 900-907.
  • 6Carrier M, Lee A Y, Bates S M,et al. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients[J]. Thromb Res, 2008,123 (1) : 177-183.
  • 7Sodeck G, Domanovits H, Schillinger M, et al. D- dimer in ruling out acute aortic dissection:a systematic review and prospective cohort study [J]. Eur Heart J,2007,28(11):3 067-3 075.
  • 8Nadir Y ,Hoffman R ,Brenner B. Drug-related throm- bosis in hematologic malignancies EJ]. Rev Clin Exp Hemato1,2004,8(1) :4.
  • 9Phrommintikul A,Haas S J ,Elsik M ,et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis[J]. Lancet, 2007,369 ( 9 559):381-388.
  • 10Canales M A,Arrieta R,Gomez-Rioja R,et al. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors[J]. J Hematother Stem Cell Res,2002,11(4) :675-681.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部